Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Anaphylaxis from medroxyprogesterone acetate.

Daniel O Selo-Ojeme1, Amna Tillisi, Christopher C Welch

  • 1Directorate of Paediatrics, Obstetrics and Gynaecology, Basildon and Thurrock University Hospitals NHS Trust, Nethermayne, Basildon, England. Dseloojeme@aol.com

Obstetrics and Gynecology
|May 4, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mentoring and the meaning of soul.

Journal of the Royal Society of Medicine·2009
Same author

Risk factors for obstetric admissions to the intensive care unit in a tertiary hospital: a case-control study.

Archives of gynecology and obstetrics·2005
Same author

Aneurysmal subarachnoid haemorrhage in pregnancy.

European journal of obstetrics, gynecology, and reproductive biology·2004
Same author

A clinico-pathological study of postcoital bleeding.

Archives of gynecology and obstetrics·2004
Same author

Pregnancy outcomes following the diagnosis of interstitial cystitis.

Gynecologic and obstetric investigation·2003
Same author

Coexistence of vulvar vestibulitis and interstitial cystitis.

Acta obstetricia et gynecologica Scandinavica·2003

Depot medroxyprogesterone acetate is a widely used injectable contraceptive. While generally safe, this case highlights the potential for serious anaphylactic reactions, emphasizing the need for practitioner preparedness.

Area of Science:

  • Reproductive Health
  • Pharmacovigilance
  • Allergy and Immunology

Background:

  • Depot medroxyprogesterone acetate (DMPA) is a progestin injectable contraceptive used by millions globally.
  • DMPA is considered a safe and effective method of reversible contraception.
  • Rare but severe adverse events associated with DMPA use necessitate ongoing safety monitoring.

Observation:

  • A 40-year-old woman experienced anaphylactic shock following intramuscular injection of 150 mg DMPA.
  • The patient had no prior history of allergies or concurrent medications that could explain the reaction.
  • A second, identical anaphylactic episode occurred upon repeat DMPA administration 12 weeks later.

Findings:

  • Anaphylaxis is a rare but serious adverse effect of depot medroxyprogesterone acetate.

Related Experiment Videos

  • The patient fully recovered after immediate medical resuscitation.
  • Recurrence of anaphylaxis confirms a causal link between DMPA and the severe allergic reaction.

    • Implications:

    • Healthcare providers must be aware of the potential for life-threatening anaphylaxis with DMPA.
    • Emergency preparedness for managing severe allergic reactions is crucial in clinical practice.
    • This case underscores the importance of vigilance in pharmacovigilance for widely used medications.